Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 62
Filter
1.
J. Health Biol. Sci. (Online) ; 11(1): 1-3, Jan. 2023. ilus
Article in English | LILACS | ID: biblio-1525592

ABSTRACT

Immune thrombocytopenia (ITP) is an acquired cause of thrombocytopenia characterized by the presence of autoantibodies against platelets. It may be primary or secondary to several conditions. We present the case of a 63-year-old woman with a diagnosis of immune thrombocytopenia refractory to conventional therapy. After she was tested for secondary causes of ITP, a diagnosis of acute cytomegalovirus (CMV) infection was made. She was treated with ganciclovir and presented normalization of platelet count. CMV-related Immune Thrombocytopenia should always be considered in certain cases of refractory ITP. If the diagnosis of ITP secondary to acute CMV infection is made, specific antiviral therapy with ganciclovir should be considered. In these cases, immunosuppressive agents, such as steroids, may worsen the ITP and should be tapered or withdrawn as rapidly as feasible.


A Púrpura Trombocitopênica Imune (PTI) é uma causa de trombocitopenia adquirida caracterizada pela presença de autoanticorpos contra plaquetas. A doença pode ser primária ou secundária a diversas condições. Apresentamos o caso de uma mulher de 63 anos com diagnóstico de PTI refratária à terapêutica convencional. A investigação de causas secundárias evidenciou infecção aguda por citomegalovírus (CMV). A paciente foi tratada com ganciclovir e evoluiu com normalização no nível de plaquetas. A PTI relacionada ao CMV deve sempre ser investigada em pacientes com PTI refratária, sendo a terapia antiviral específica com ganciclovir o tratamento de escolha. Nestes casos, os agentes imunossupressores, como os corticosteroides, podem piorar a PTI e devem ser reduzidos gradualmente ou retirados o mais rapidamente possível.


Subject(s)
Humans , Female , Middle Aged
2.
Cienc. Salud (St. Domingo) ; 7(1): [65-74], 2023.
Article in Spanish | LILACS | ID: biblio-1444357

ABSTRACT

Introducción: los cambios en el ácido desoxirribonucleico se conocen como mutaciones, estas dan lugar a los polimorfismos, los cuales generan variación alélica entre individuos y diversidad de la misma especie. Se ha sugerido que los polimorfismos genéticos en los mediadores inmunitarios desempeñan un papel fundamental en la patogénesis de muchos trastornos autoinmunes, como en la púrpura trombocitopénica inmune, siendo esta el tipo más común de púrpura trombocitopénica y, a menudo, se diagnostica como un tipo de trastorno autoinmune, debido a la destrucción de las plaquetas mediadas por el sistema inmunitario. Objetivo: realizar una revisión bibliográfica sobre el papel de los polimorfismos genéticos y su influencia en el desarrollo de la púrpura trombocitopénica inmune. Métodos: se realizó revisión literaria en inglés y español en PubMed y Elsevier, desde marzo hasta mayo del 2021, con el uso de combinación de palabras clave y términos MeSH, como púrpura trombocitopénica y polimorfismos genéticos. Se realizó análisis y resumen de la literatura encontrada. Conclusión: la púrpura trombocitopénica inmune es considerada como una patología multifactorial, causada por factores ambientales y genéticos, dentro de los cuales se encuentran los polimorfismos para los mediadores inmunitarios que pueden llevar a una exacerbación de la enfermedad o no intervenir en la misma.


Introduction: Changes in deoxyribonucleic acid are known as mutations, these give place to polymorphisms, which generate allelic variation between individuals and provide diversity among same species. Genetic polymorphisms in immune mediators have been suggested to play a key role in the pathogenesis of many autoimmune disorders, such as immune thrombocytopenic purpura, this being the most common type of thrombocytopenic purpura and is often diagnosed as a type of autoimmune disorder, due to the destruction of platelets mediated by the immune system. Objective: To execute a bibliographic review on the role of genetic polymorphisms and their influence on the development of immune thrombocytopenic purpura. Methods: A literary review in English and Spanish was performed in PubMed and Elsevier from March to May 2021, with the use of a combination of keywords and MeSH terms such as Thrombocytopenic Purpura and genetic polymorphisms. Analysis and summary of the literature found was executed. Conclusion: Immune thrombocytopenic purpura is considered a multifactorial pathology, caused by environmental and genetic factors, among which are polymorphisms for immune mediators that can lead to an exacerbation of the disease or not intervene in the same.


Subject(s)
Polymorphism, Genetic , Purpura, Thrombocytopenic , Blood Platelets , Risk Factors , Hematologic Diseases
3.
Rev. med. Urug ; 38(4): e38412, dic. 2022.
Article in Spanish | LILACS, BNUY | ID: biblio-1424181

ABSTRACT

La púrpura trombótica trombocitopénica (PTT) es una microangiopatía trombótica poco frecuente, que se caracteriza por anemia hemolítica y plaquetopenia, con una elevada morbimortalidad. Su forma más frecuente es la PTT inmune, también denominada adquirida, provocada por la deficiencia de la enzima disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) secundaria a la presencia en plasma de autoanticuerpos. Presentamos el caso de un paciente con diagnóstico de pancreatitis aguda (PA) complicada con PTT, asociación de presentación excepcional en la práctica clínica.


Summary: Thrombotic thrombocytopenic purpura is rather an unusual thrombotic microangiopathy characterized by hemolytic anemia and plateletopenia which results in high morbimortality rates. The most frequent form of this disease is immune thrombotic thrombocytopenic purpura, also known as acquired thrombotic thrombocytopenic purpura, which is caused by enzime deficiency disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) that is secondary to antibodies in plasma. The study presents the case of a patient with a diagnosis of acute pancreatitis with a rare complication of thrombotic thrombocytopenic purpura which is exceptional in the clinical practice.


A púrpura trombocitopênica trombótica (PTT) é uma microangiopatia trombótica rara, caracterizada por anemia hemolítica e trombocitopenia, com alta morbimortalidade. Sua forma mais comum é a TTP imune, também conhecida como adquirida, que é causada pela deficiência da enzima ADAMTS13 (em inglês A disintegrin-like and metalloprotease with thrombospondin type 1 motif no. 13) secundária à presença de autoanticorpos no plasma. Apresentamos o caso de um paciente com diagnóstico de pancreatite aguda (PA) complicada por PTT, associação com apresentação excepcional na prática clínica.


Subject(s)
Pancreatitis/complications , Purpura, Thrombotic Thrombocytopenic , Thrombotic Microangiopathies , Acute Disease
4.
Rev. peru. med. exp. salud publica ; 39(1): 111-114, ene.-mar. 2022. tab, graf
Article in Spanish | LILACS | ID: biblio-1389936

ABSTRACT

RESUMEN Durante la infección aguda por el SARVS-CoV-2 se produce una desregulación del sistema inmune que puede durar hasta ocho meses después de controlado el cuadro agudo. Esto, sumado a otros factores, posiblemente este asociado con un aumento del riesgo de aparición y concurrencia de enfermedades autoinmunes. La aparición simultanea del síndrome de Guillain-Barré (SGB) y púrpura trombocitopénica (PTI) se ha reportado poco en la literatura, y el SGB raramente se asocia con otra enfermedad autoinmune. Presentamos el caso de un varón que luego de un mes de tener un cuadro agudo de COVID-19 moderado, presentó concurrentemente SGB y PTI con respuesta adecuada al tratamiento.


ABSTRACT During acute SARS-CoV-2 infection, there is persistent deregulation of the immune system that can last up to 8 months after the acute condition is controlled. This, added to other factors, is possibly associated with an increased risk of the appearance and concurrence of autoimmune diseases. The simultaneous occurrence of GBS and ITP has been rarely reported in the literature, and GBS is rarely associated with another autoimmune disease. We present the case of a man who, one month after his recovery from acute moderate COVID-19, presented concurrent GBS and ITP with an adequate response to treatment.


Subject(s)
Humans , Male , Purpura, Thrombocytopenic, Idiopathic , Guillain-Barre Syndrome , SARS-CoV-2 , COVID-19 , Autoimmune Diseases , Thrombocytopenia , Autoimmunity , Autoimmune Diseases of the Nervous System , Demyelinating Autoimmune Diseases, CNS
5.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1390279

ABSTRACT

RESUMEN Se presenta el caso de un paciente masculino con púrpura trombocitopénica inmunológica que ocurre 10 días después de la aplicación de la vacuna contra la COVID-19. Se descartaron con estudios complementarios todas las causas secundarias. Con pulsos de corticoides presentó mejoría clínica y laboratorial, evolucionando favorablemente. Asumiendo la relación temporal con dicha vacuna, se presume que esta plaquetopenia fue una reacción adversa a la misma. En el país no se han notificado casos de púrpura trombocitopénica inmunológica hasta el último boletín informativo de reacciones adversas relacionadas a esta vacuna.


ABSTRACT We present the case of a male patient with immunological thrombocytopenic purpura that occurs 10 days after the application of the COVID-19 vaccine. All secondary causes were ruled out with complementary studies. With corticosteroid pulses, he presented clinical and laboratory improvement, progressing favorably. Assuming the temporal relationship with the vaccine, it is presumed that this thrombocytopenia was an adverse reaction to it. No cases of immune thrombocytopenic purpura have been reported in the country until the last bulletin of adverse reactions related to this vaccine.

6.
Clin. biomed. res ; 42(2): 176-185, 2022.
Article in Portuguese | LILACS | ID: biblio-1391647

ABSTRACT

Helicobacter pylori, uma bactéria gram-negativa, desde 1984 vem sendo associada às doenças gástricas. A partir da década de 1990, surgiram crescentes relatos indicando a relação da infecção com manifestações extragástricas. Nesse sentido, o objetivo do estudo foi investigar, através de uma revisão integrativa, as evidências relacionadas à H. pylori e a presença de doenças hematológicas, focando na anemia por deficiência de ferro (ADF) e na púrpura trombocitopênica idiopática (PTI). Bases de dados foram consultadas com as palavras-chave e descritores Helicobacter pylori, Doenças extragástricas, Doenças hematológicas, Anemia ferropriva e Púrpura Trombocitopênica Idiopática, nos idiomas inglês, português e espanhol, combinados com o operador booleano "AND". Após a leitura de 1.964 títulos, 85 artigos atendiam aos critérios de inclusão. Com a exclusão dos artigos duplicados e pela análise dos resumos, 62 trabalhos foram selecionados e lidos na íntegra. Por fim, 27 estudos foram incluídos: 13 relacionados à ADF e 77% deles encontraram associação com H. pylori, e 14 relacionados à PTI, nos quais a relação com a bactéria foi encontrada em 93%. As evidências que associam essas doenças hematológicas com H. pylori são expressivas, portanto, mais estudos são necessários para elucidar os mecanismos relacionados e contribuir para prevenção, diagnóstico e tratamento mais eficazes.


Helicobacter pylori is a gram-negative bacterium that has been associated with gastric diseases since 1984. Since the 1990s, there have been increasing reports indicating that the infection may also be associated with extragastric manifestations. This integrative review aimed to investigate the evidence on the relationship between H. pylori and hematological diseases, specifically iron deficiency anemia (IDA) and idiopathic thrombocytopenic purpura (ITP). Databases were searched for the keywords "Helicobacter pylori," "extragastric diseases," "hematologic diseases," "iron deficiency anemia," and "idiopathic thrombocytopenic purpura" in English, Portuguese, and Spanish, combined with the boolean operator "AND." The search yielded 1,964 studies. After reading the titles, only 85 met the inclusion criteria. Sixty-two studies were selected for full-text reading after exclusion of duplicates and abstract analysis. Finally, 27 studies were included in this review. Thirteen studies addressed IDA, among which 77% found an association with H. pylori; whereas 14 studies addressed ITP, among which 93% found a relationship with H. pylori. There is strong evidence supporting the association between hematologic diseases and H. pylori. Further studies are needed to elucidate the mechanisms involved in this relationship, contributing to more effective prevention, diagnosis, and treatment.


Subject(s)
Humans , Helicobacter pylori , Helicobacter Infections/complications , Purpura, Thrombocytopenic, Idiopathic/virology , Anemia, Iron-Deficiency/virology
7.
Pediátr. Panamá ; 50(3): 13-15, 30 diciembre 2021.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1352576

ABSTRACT

El síndrome de Evans se caracteriza por la presentación simultánea de anemia hemolítica autoinmune y púrpura trombocitopénica inmune, puede presentarse como una patología aislada o como manifestación de una enfermedad sistémica. Caso Clínico: Preescolar masculino de 3 años, diagnosticado de síndrome de Evans, requirió tratamiento con corticoides e inmunoglobulina por mala respuesta inmunológica, tres meses después de su diagnóstico inicial presento afectación renal, además de presentar autoanticuerpos positivos, por lo que se estableció diagnóstico de lupus eritematoso sistémico. Conclusión: El síndrome de Evans es una entidad nosológica poco frecuente, ante su diagnóstico se debe descartar enfermedad sistémica subyacente.


Evans syndrome is characterized by the simultaneous presentation of autoimmune hemolytic anemia and immune thrombocytopenic purpura; it can be manifested as an isolated pathology or as a manifestation of a systemic disease. Clinical Case: 3-year-old preschool male, diagnosed with Evans syndrome, that required corticosteroids and immunoglobulin intravenous treatment due to poor immune response. Three months after his initial diagnosis he presents kidney affectation in addition to presenting positive auto-antibodies, with which it was established the diagnosis of systemic lupus erythematosus. Conclusion: Evans syndrome is a rare nosological entity, when the diagnosis is made an underlying systemic disease must be ruled out.

8.
Rev. Círc. Argent. Odontol ; 79(230): 21-23, dic. 2021. ilus
Article in Spanish | LILACS | ID: biblio-1358320

ABSTRACT

La PTI es una alteración hemorrágica de instalación súbdita, adquirida, que se manifiesta inicialmente con petequias, equimosis o hematomas en piel y mucosas, sangrado nasal y gingival, sin causa aparente. La mucosa bucal puede ser el sitio donde las lesiones se observen con frecuencia y por primera vez. Se reporta el caso de un paciente masculino de 28 años de edad, con manifestaciones clínicas de un cuadro purpúrico, se describen signos, síntomas, terapéutica y manejo estomatológico (AU)


PTI is a hemorrhagic alteration of sudden installation, acquired, which manifests initially with petechiae, esquimosis or bruises on skin and mucosae, nasal and gingival bleeding without apparent cause. Bucal mucosae can be the site where lesions are observed with frequency, and for the first time. The case of a male patient with 28 years of age with clinical manifestationsofpurpuric syndrome is reported, signs, symptoms, therapeutic and stomatological handling are described (AU)


Subject(s)
Humans , Male , Adult , Gingival Hemorrhage , Purpura, Thrombocytopenic, Idiopathic , Mouth Mucosa/injuries , Signs and Symptoms , Immunoglobulins , Ecchymosis , Rituximab , Glucocorticoids
9.
Acta méd. costarric ; 63(4)dic. 2021.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1505481

ABSTRACT

El virus SARS-CoV-2 produce una enfermedad con múltiples manifestaciones clínicas. Los hallazgos hematológicos anormales, entre ellos la trombocitopenia, han surgido como una complicación emergente de la COVID-19. A nivel mundial, se han descrito casos que asocian la infección por el virus SARS-CoV-2 con la trombocitopenia inmune; sin embargo, este es el primer registro publicado en Costa Rica a la fecha. En este reporte clínico se describe una paciente adulta mayor atendida en el Centro Especializado para la Atención de pacientes COVID-19, uno de los hospitales de la Caja Costarricense de Seguro Social. Ingresó con cuadro de COVID-19 severo que, durante su estancia hospitalaria, desarrolló plaquetopenia aguda asintomática. Posterior a la exclusión de otros diagnósticos causales de este signo clínico, se hizo diagnóstico de trombocitopenia inmune con asociación a SARS-CoV-2 Además del manejo protocolizado por la COVID-19 que incluyó dexametasona y enoxaparina, recibió un ciclo adicional de dexametasona junto con una dosis de inmunoglobulina intravenosa, tras lo cual presentó una recuperación completa del conteo plaquetario.


The SARS-CoV-2 virus is a disease that produces multiple clinical manifestations. Abnormal hematologic findings, such as thrombocytopenia, have emerged as a complication of COVID-19. Worldwide, series of cases of association between the SARS-CoV-2 virus and immune thrombocytopenia have been described; however, reported to date, it is the first case published in Costa Rica. This clinical report describes the case of an elderly female admitted in the Centro Especializado para la Atención de pacientes COVID-19, one of the hospitals of the Caja Costarricense de Seguro Social. She was admitted with severe COVID-19, and during her hospital stay, she developed asymptomatic acute thrombocytopenia. The diagnosis of immune thrombocytopenia was made after excluding other diagnoses causing this sign. In addition of the protocolized management of COVID-19 with steroids and enoxaparin, she was treated with an additional cycle of dexamethasone and a dose of intravenous immunoglobulin. After this, she showed a complete recovery of the platelet count.

10.
Iatreia ; 34(3)sept. 2021.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1534571

ABSTRACT

Introducción: la púrpura trombocitopénica inmune (PTI) es una manifestación hematológica frecuente en el lupus eritematoso sistémico (LES). Los corticoesteroides son la primera línea de manejo para la trombocitopenia moderada o grave, en conjunto con antimaláricos y otros inmunosupresores. En casos particulares, en donde la respuesta a las intervenciones iniciales no sea la adecuada, se cuenta con terapias de segunda línea. Objetivo: esta revisión narrativa se enfocará en dos medicamentos agonistas del receptor de trombopoyetina (RTPO): eltrombopag y romiplostim y en su papel en la PTI secundaria a LES. Además, se revisará su perfil farmacológico, dosis e indicaciones en el contexto de esta enfermedad. Métodos: se realizó una búsqueda de literatura en diferentes bases de datos, se analizaron artículos científicos y guías de manejo, tanto de LES como de trombocitopenia inmune, con el fin de contestar diferentes preguntas clínicas surgidas en el escenario de la práctica cotidiana. Resultados y conclusiones: el uso de los estimulantes de TPO es una alternativa terapéutica para escenarios particulares de pacientes con LES y trombocitopenia inmune. Sin embargo, son necesarios estudios enfocados en esta población específica para poder hacer recomendaciones acertadas acerca de su manejo. Los datos actuales son extrapolados de la trombocitopenia inmune primaria.


SUMMARY Introduction: Immune thrombocytopenia is a frequent hematologic manifestation in systemic lupus erythematosus (SLE). Corticosteroids are the first line of treatment for moderate to severe thrombocytopenia in this disease, in conjunction with antimalarials or other immunosuppressants. In particular cases where the response to initial interventions is not achieved, second-line therapies with different mechanisms of action are available. Objective: This narrative review will focus on two thrombopoietin receptor agonist drugs (TPO-RA): eltrombopag and romiplostim, and their role in immune thrombocytopenia secondary to SLE. In addition, its pharmacological profile, dose and indications will be reviewed in the context of this disease. Methods: A literature search was conducted in different databases; scientific articles and guidelines were analyzed, both for SLE and immune thrombocytopenia. With the purpose of answering different clinical questions that constantly arise in the scene of daily practice. Results and conclusions: The use of TPO-RA stimulants is a therapeutic alternative for particular scenarios in patients with SLE and immune thrombocytopenia, however studies focused on this particular population are necessary to be able to make strong recommendations about its utility. Current data are extrapolated from primary immune thrombocytopenia.

11.
CES med ; 35(2): 193-201, mayo-ago. 2021. graf
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1364615

ABSTRACT

Resumen En la trombocitopenia autoinmune primaria hay formación de autoanticuerpos contra las membranas plaquetarias causando destrucción plaquetaria esplénica y compromiso clínico consistente en petequias, hemorragias y trombocitopenia. Cuando falla el manejo médico con corticoides e inmunoglobulinas está indicada la realización de esplenectomía, que funciona para remisión parcial de la enfermedad persistente. Realizar la esplenectomía hace necesario el estudio de un bazo accesorio o material esplénico recurrente, que comúnmente se asocia con la pobre respuesta a tratamiento y recaídas de la enfermedad. Se presenta el caso de una paciente de 27 años y antecedentes de trombocitopenia autoinmune primaria quien requirió esplenectomía, con adecuada evolución postoperatoria y remisión de los síntomas por dos años. Posteriormente, presentó recaída clínica y paraclínica, con plaquetas en 11 000 cel/uL, en contexto de trombocitopenia severa sintomática, presencia de gingivorragia, petequias en los miembros inferiores y el abdomen. Se realizó búsqueda activa de bazo supernumerario por medio de estudios complementarios, los cuales evidenciaron bazo accesorio localizado en el ligamento gastro cólico, que fue resecado por vía laparoscópica, con adecuada respuesta y remisión sintomática de la trombocitopenia autoinmune primaria refractaria. En pacientes esplenectomizados con púrpura trombocitopénica idiopática que tengan recaída de su enfermedad se requiere búsqueda activa de bazos supernumerarios, puesto que es una causa frecuente de su reaparición.


Abstract In primary autoimmune thrombocytopenia there is formation of autoantibodies against the splenic platelet membranes causing platelet destruction with clinical deterioration consisting of petechiae, haemorrhages and thrombocytopenia. When the medical management with corticoids and immunoglobulins fails, it is indicated the accomplishment of splenectomy that works for partial remission of the persistent disease. Performing splenectomy requires the study of an accessory spleen or the recurrent splenic material, that is commonly associated with poor response to treatment and frequent relapses of primary autoimmune thrombocytopenia. A case is presented in a 27-year-old patient with a history of primary autoimmune thrombocytopenia requiring splenectomy, with adequate postoperative evolution and remission of symptoms for two years who later presents clinical and paraclinical relapse with platelets at 11,000 cells/uL in the context of severe symptomatic thrombocytopenia, with the presence of gingivorrhagia, petechiae in the lower limbs and abdomen. Active search of supernumerary spleen was performed by means of complementary studies that showed an accessory spleen located in the gastrocolic ligament, which was resected by laparoscopy with adequate symptomatic remission response of the refractory primary autoimmune thrombocytopenia. In splenectomized patients with idiopathic thrombocytopenic purpura who have relapsed their disease, they require an active search for supernumerary spleens since it is a frequent cause of their reappearance.

12.
Rev. cuba. hematol. inmunol. hemoter ; 37(2): e1235, 2021. graf
Article in Spanish | LILACS, CUMED | ID: biblio-1289431

ABSTRACT

Introducción: La púrpura trombocitopénica trombótica puede presentarse en menos del 2 por ciento de los pacientes con lupus eritematoso sistémico. Esta asociación implica un aumento de la mortalidad y un periodo de remisión más prolongado. Objetivo: Se presenta el caso de paciente peruana que desarrolló esta asociación y presentó complicaciones relacionadas con shock séptico. Caso clínico: Paciente femenina, con antecedente de púrpura trombocitopénica inmunológica y lupus eritematoso sistémico, acudió a emergencia por presentar palidez cutánea generalizada, petequias en miembros inferiores y hematuria. Posteriormente, su estado de salud se complicó con un shock séptico y deterioro del nivel de conciencia. Por todo esto, es referida a un hospital de mayor complejidad y hace su ingreso a la unidad de cuidados intensivos. La clínica y los exámenes de laboratorio revelaron hallazgos compatibles con púrpura trombocitopénica trombótica (anemia grave, plaquetopenia, esquistositosis) y lupus eritematoso sistémico activo grave. Antes de ser referida, recibió pulsos de metilprednisona y prednisona. Ya en unidad de cuidados intensivos, se cambió a soporte ventilatorio y tratamiento antibiótico. Con el diagnóstico presuntivo de púrpura trombocitopénica trombótica, asociada a lupus eritematoso sistémico activo grave, se inició tratamiento oportuno con plasmaféresis, corticoterapia y ciclofosfamida. La paciente recuperó los niveles plaquetarios y el nivel óptimo de conciencia. Actualmente acude a controles. Conclusiones: La púrpura trombocitopénica trombótica es una emergencia hematológica con alta mortalidad en ausencia de tratamiento. Su reconocimiento oportuno, sin dosificación de la proteína ADAMTS13, en esta asociación poco frecuente con lupus eritematoso sistémico es importante en el buen pronóstico del paciente(AU)


Introduction: Thrombotic thrombocytopenic purpura may occur in less than 2 percent of patients with systemic lupus erythematosus. This association implies an increase in mortality and a longer remission period. Objective: We present the case of a Peruvian woman who developed this association, and complicating herself with septic shock. Clinical case: A female patient, with a history of immunological thrombocytopenic purpura and systemic lupus erythematosus, comes to the emergency room due to generalized skin pallor, lower limb petechiae and hematuria. Subsequently, her state of health gets complicated with a septic shock and deterioration of the level of consciousness. For all of this, she was referred to a hospital of greater complexity and makes admission to an intensive care unit. Clinical and laboratory tests revealed findings compatible with thrombotic thrombocytopenic purpura (severe anemia, platelet disease, schistositosis) and severe active systemic lupus erythematosus. Before being referred, she received pulses of methylprednisone and prednisone. When already in the intensive care unit, it was changed to ventilatory support andantibiotic treatment. With the presumptive diagnosis of thrombotic thrombocytopenic purpura, associated with severe active systemic lupus erythematosus, a timely treatment was initiated with plasmapheresis, corticosteroids and cyclophosphamide. The patient recovered platelet levels and optimal level of consciousness. She is currently going to controls. Conclusions: Thrombotic thrombocytopenic purpura is a hematological emergency with high mortality in the absence of treatment. Its timely recognition, without dosing of ADAMTS13 protein, in this rare association with systemic lupus erythematosus is important in the good prognosis of the patient(AU)


Subject(s)
Humans , Female , Purpura, Thrombocytopenic/complications , Plasmapheresis/methods , Intensive Care Units , Lupus Erythematosus, Systemic/complications , Purpura, Thrombocytopenic/drug therapy
13.
Rev. chil. infectol ; 38(1): 108-113, feb. 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1388197

ABSTRACT

Resumen Las manifestaciones hematológicas de la infección por el VIH son frecuentes y variadas debido a su capacidad de afectar prácticamente todas las líneas celulares. Dentro de éstas, la púrpura trombocitopénica trombótica (PTT) es una de las entidades que constituyen las microangiopatías trombóticas. Se caracteriza por la presencia de trombocitopenia y anemia hemolítica microangiopática con alteración de la función renal. Actualmente, la co-existencia de estas dos entidades es poco frecuente debido a la terapia anti-retroviral de alta efectividad (TARV) Presentamos el caso de un paciente de 28 años, quien consultó por fiebre asociada a episodios de gingivorragia, palidez mucocutánea generalizada y debilidad progresiva. Los estudios evidenciaron una anemia y trombocitopenia grave. Se encontraron esquistocitos y microesferocitos en el frotis de sangre periférica con actividad de la enzima ADAMTS 13 disminuida (6,8%). Se confirmó el diagnóstico de una PTT como manifestación inicial de una infección por VIH. Se indicó manejo con plasmaféresis e inicio de TARV con buena respuesta.


Abstract Hematological manifestations for human immunodeficiency virus (HIV) infection are frequent and diverse due to its ability to affect almost all cell lines. Among these, thrombotic thrombocytopenic purpura (TTP) is one of the thrombotic microangiopathies syndromes, characterized by the presence of thrombocytopenia and microangiopathic hemolytic anemia with impaired renal function. Nowadays, the relationship between these two entities is rare given the current highly active antiretroviral therapy (HAART). We report the case of a 28-year-old patient, who presented with fever associated with gingival bleeding, generalized mucocutaneous pallor and progressive weakness. Routine investigations showed anemia and severe thrombocytopenia, schistocytes and micro spherocytes in peripheral blood smear. Required blood transfusion, with decreased ADAMTS 13 enzyme activity (6.8%). With these findings,TTP was diagnosed as the initial manifestation of the HIV infection. The patient received management with five sessions of plasmapheresis and HAART with subsequent improvement.


Subject(s)
Humans , Male , Adult , Purpura, Thrombotic Thrombocytopenic , HIV Infections , Anemia, Hemolytic , Purpura, Thrombotic Thrombocytopenic/diagnosis , Purpura, Thrombotic Thrombocytopenic/therapy , HIV Infections/complications , HIV Infections/drug therapy , Plasmapheresis
14.
Med. lab ; 25(2): 485-499, 2021. tabs
Article in Spanish | LILACS | ID: biblio-1293234

ABSTRACT

La microangiopatía trombótica (MAT) es un síndrome donde hay formación de microtrombos en la circulación que llevan a anemia hemolítica microangiopática (AHMA) y trombocitopenia con falla multiorgánica, debido a la isquemia de los tejidos. Las MAT pueden ser primarias sin causa subyacente asociada, como la púrpura trombocitopénica trombótica debida a deficiencia de la enzima ADAMTS13, el síndrome hemolítico urémico debido a la toxina Shiga de Escherichia coli enterohemorrágica, y la MAT producida por alteraciones en la regulación del complemento. Adicionalmente, pueden ser secundarias a enfermedades malignas, infecciosas, metabólicas, autoinmunes o inducidas por el embarazo. Estas patologías requieren diagnóstico y tratamiento oportunos debido a que tienen alta morbimortalidad y se asocian a complicaciones que incluyen enfermedad renal, alteraciones neurológicas como convulsiones, accidente cerebrovascular, coma y muerte. El tratamiento es multidisciplinario y se enfoca en el soporte hemodinámico, transfusional y en el manejo de la etiología cuando esta es identificada. La siguiente revisión pretende explicar de forma clara y precisa los aspectos generales de las MAT primarias


Thrombotic microangiopathy (TMA) is a syndrome characterized by the formation of microthrombi in the circulation leading to microangiopathic hemolytic anemia (MAHA) and thrombocytopenia, with multiorgan failure due to tissue ischemia. TMA can be primary with no associated underlying cause, such as thrombotic thrombocytopenic purpura due to ADAMTS13 deficiency, hemolytic uremic syndrome due to the Shiga toxin from enterohemorrhagic Escherichia coli, or due to complement dysregulation. Furthermore, TMA can be secondary to malignant, infectious, metabolic or autoimmune diseases, or induced by pregnancy. These conditions require a timely diagnosis and treatment due to their associated high morbidity and mortality, and complications like renal disease, neurological disorders such as seizures, stroke, coma and death. Treatment is multidisciplinary and focuses on hemodynamic and transfusion support, and on the management of the etiology when it is identified (daily plasma exchange, eculizumab or management of underlying disease). This review aims to discuss the general aspects of primary thrombotic microangiopathies


Subject(s)
Thrombotic Microangiopathies , Purpura, Thrombotic Thrombocytopenic , Thrombocytopenia , Atypical Hemolytic Uremic Syndrome , Hemolytic-Uremic Syndrome , Anemia, Hemolytic
15.
J. Bras. Patol. Med. Lab. (Online) ; 57: e2472021, 2021. tab
Article in English | LILACS-Express | LILACS | ID: biblio-1154602

ABSTRACT

ABSTRACT INTRODUCTION: Idiopathic thrombocytopenic purpura (ITP) is an acquired immune disorder that causes a reduction in platelet count, called thrombocytopenia. ITP during pregnancy usually presents some complications that may impair the outcome of pregnancy. OBJECTIVE: This literature review aimed to identify the main complications of ITP in pregnancy and its consequences. METHODOLOGY: The bibliographic search was performed through scientific articles available in the Scielo and PubMed databases, of which 64 articles were selected, both in Portuguese and English. RESULTS: The risk of postpartum hemorrhage, placental abruption, and neonatal thrombocytopenia are some complications that may occur during pregnancy. CONCLUSION: Pregnant women must be properly monitored during pregnancy so that there are no major complications.


RESUMEN INTRODUCCIÓN: La púrpura trombocitopénica idiopática (PTI) es una enfermedad autoinmune adquirida que causa un bajo conteo de plaquetas en la sangre denominado trombocitopenia. La PTI durante el embarazo normalmente presenta algunas complicaciones que pueden afectar el resultado del embarazo. OBJETIVO: Esta revisión de literatura tuvo como objeto identificar las principales complicaciones de la PTI en el embarazo y sus consecuencias. MÉTODO: Se llevó a cabo una búsqueda bibliográfica de artículos científicos disponibles en las bases de datos Scielo y PubMed. Se seleccionaron 64 artículos, tanto en inglés como en portugués. RESULTADOS: El riesgo de hemorragia posparto, desprendimiento prematuro de placenta y trombocitopenia neonatal son algunas complicaciones que pueden ocurrir en la gestación. CONCLUSIÓN: Las mujeres embarazadas deben ser debidamente supervisadas durante el embarazo para que no ocurran mayores complicaciones.


RESUMO INTRODUÇÃO: A púrpura trombocitopênica idiopática (PTI) é uma doença autoimune adquirida que causa redução na contagem de plaquetas denominada trombocitopenia. A PTI durante a gestação normalmente apresenta algumas complicações que podem afetar o desfecho da gravidez. OBJETIVO: Esta revisão da literatura teve como objetivo identificar as principais complicações da PTI na gravidez e suas consequências. METODOLOGIA: A pesquisa bibliográfica foi realizada por meio de artigos científicos disponíveis nas bases de dados Scielo e PubMed. Foram selecionados 64 artigos, tanto em inglês quanto em português. RESULTADOS: O risco de hemorragia pós-parto, descolamento prematuro da placenta e trombocitopenia neonatal são algumas complicações que podem ocorrer na gestação. CONCLUSÃO: As gestantes devem ser devidamente acompanhadas durante a gestação para que não ocorram maiores complicações.

16.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1390227

ABSTRACT

RESUMEN La trombocitopenia inmune primaria (PTI) es un desorden que tiene como característica el aumento de la destrucción de las plaquetas o disminución en su producción resultando niveles bajos de las mismos y un riesgo aumentado de sangrado. Se presenta el caso de un paciente de sexo masculino, de 27 años de edad, previamente sano, que acude a consulta por cuadro de 48 hs de evolución de aparición de petequias. Durante su evolución presenta hemorragia cerebelosa con hipertensión endocraneana aguda que lo lleva al óbito a pesar del tratamiento.


ABSTRACT Primary immune thrombocytopenia (ITP) is a disorder characterized by an increase in the destruction of platelets or a decrease in their production, resulting in low levels of platelets and an increased risk of bleeding. We present the case of a 27-year-old male patient, previously healthy, who came to consultation due to a 48-hour history of appearance of petechiae. During his evolution, he presented cerebellar hemorrhage with acute endocranial hypertension that led him to death despite treatment.

17.
Einstein (Säo Paulo) ; 18: eRC5111, 2020. graf
Article in English | LILACS | ID: biblio-1056048

ABSTRACT

ABSTRACT Situs inversus totalis is a rare recessive autosomal congenital abnormality in which the mediastinal and abdominal organs are in a mirrored position when compared to the usual topography. The literature reports some cases of situs inversus totalis and concomitant conditions: spinal abnormalities, cardiac malformations and hematological diseases, such as idiopathic thrombocytopenic purpura, which is an autoimmune disease that causes thrombocytopenia due to platelet destruction or suppression of its production. This article aimed to report the coexistence of situs inversus totalis and idiopathic thrombocytopenic purpura.


RESUMO Situs inversus totalis é uma anormalidade congênita autossômica recessiva rara em que os órgãos mediastinais e abdominais encontram-se em posição espelhada em relação à topografia habitual. A literatura relata alguns casos de concomitância do situs inversus totalis com outras condições: anomalias espinhais, malformações cardíacas e doenças hematológicas, como púrpura trombocitopênica idiopática, que é uma doença autoimune com plaquetopenia, devido à destruição dos trombócitos ou supressão da sua produção. Esse artigo teve o objetivo de relatar coexistência de situs inversus totalis e púrpura trombocitopênica idiopática.


Subject(s)
Humans , Male , Young Adult , Situs Inversus/complications , Situs Inversus/diagnostic imaging , Purpura, Thrombocytopenic, Idiopathic/complications , Situs Inversus/pathology , Radiography, Panoramic , Tomography, X-Ray Computed
18.
Arch. argent. pediatr ; 117(6): S243-S254, dic. 2019. Tab, graf
Article in Spanish | BINACIS, LILACS | ID: biblio-1051620

ABSTRACT

El manejo de la trombocitopenia inmune es motivo de discusión en lo concerniente a evolución,diagnóstico, pronóstico y tratamiento. Se han publicado arias guías que expresan distintas opiniones de expertos, pero no existe aún consenso mundial sobre cuál es el manejo más adecuado de la enfermedad. Esta guía establece los criterios para definir el diagnóstico; detalla el plan de estudios de laboratorio por realizar inicialmente; plantea los distintos diagnósticos diferenciales; desarrolla aspectos relativos a evolución y pronóstico, y enumera los tratamientos disponibles para las formas agudas y las crónicas, así como para el manejo de las emergencias y en algunas situaciones especiales.


Management, outcome, diagnosis, prognosis and treatment of immune thrombocytopenia are controversial. Several guidelines stating different experts' opinions have been published; however, no worldwide consensus regarding the management of the disease has still been reached. This guideline defines diagnostic criteria, states initial laboratory tests, establishes differential diagnosis, develops topics concerning outcome and prognosis, and enumerates available treatments for acute and chronic disease, as well as for management of life-threatening bleeding.


Subject(s)
Humans , Purpura, Thrombocytopenic, Idiopathic/diagnosis , Purpura, Thrombocytopenic, Idiopathic/therapy , Pediatrics
19.
Rev. cientif. cienc. med ; 22(2): 7-14, 2019. ilus
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1126261

ABSTRACT

Introducción: La purpura trombocitopénica idiopática es un trastorno adquirido causado por auto-anticuerpos contra antígenos plaquetarios.A la fecha no se han estudiado las características clínicas y respuesta al tratamiento en Bolivia. Objetivo: Describir las características clínicas y resultados del tratamiento en pacientes adultos con purpura trombocitopénica idiopática de reciente diagnóstico. Métodos: Se realizó un estudio descriptivo, retrospectivo de una serie de casos de adultos con púrpura trombocitopénica idiopática en un Servicio de Hematología de La Paz, Bolivia durante el periodo 2009-2014. Resultados: El análisis incluyó 23 pacientes con una edad media de 59,9 años. Al diagnóstico todos los pacientes presentaron manifestaciones hemorrágicas (nasal 82,6%, cutáneo 56,5%, y oral 34,78%), la media del recuento plaquetario al diagnóstico fue de 26.7 x 109/L. Se detectó anticuerpos contra Helicobacter pylori en 4 de 6 que contaban con esta prueba. El hallazgo más frecuente en médula ósea fue la presencia de un número aumentado o normal de megacariocitos. La respuesta al tratamiento de primera línea fue del 96% (RC: 61%, R: 35%). Tras una media de seguimiento de 24 meses, el 60% de los pacientes presentaron recaída en un promedio de 12,5 meses desde el diagnóstico. Conclusiones: Al momento del diagnóstico las manifestaciones hemorrágicas son las más frecuentes, los recuentos plaquetarios por lo general son inferiores a 30 x 109/L. Los corticoides son el tratamiento inicial de elección, con respuestas favorables en la mayoría de los pacientes, sin embargo, más de la mitad de los pacientes presentan recaída en tiempo promedio de 1 año.


Introduction: Idiopathic thrombocytopenic purpura is an acquired disorder caused by autoantibodies against platelet antigens. To date have not been studied the clinical characteristics and treatment response in Bolivia. Objective: To describe the clinical characteristics and treatment outcomes in adult patients with newly diagnosed immune thrombocytopenic purpura. Methods: A descriptive, retrospective study of an adult case series with immune thrombocytopenic purpura was performed in a Hematology Service of La Paz, Bolivia during the period 2009-2014. Results: We included 23 patients with a median age of 59.9 years. All patients had hemorrhagic manifestations at diagnosis (nasal 82.6%, oral 56.5% and cutaneous 34.78%). The average platelet count was 26.7 x 109/L. The presence of antibodies against Helicobacter pylori was detected in 4 of 6 patients. The presence of normal or increased megakaryocyte numbers was the predominant finding in bone marrow. The response to first-line treatment was 96% (CR: 61%, R: 35%).After a mean follow-up of 24 months, 60% of the patients had a relapse in an average of 12.5 months from diagnosis. Conclusions: At the time of diagnosis, hemorrhagic manifestations are the most frequent, platelet counts are usually less than 30x109/L. Corticosteroids are the initial treatment of choice, with favorable responses in the majority of patients, however, more than half of the patients present relapse in an average time of 1 year.

20.
Gac. méd. boliv ; 41(2): 37-42, Dec. 2018. ilus., tab.
Article in Spanish | LILACS, LIBOCS | ID: biblio-988186

ABSTRACT

La púrpura trombocitopénica inmune es un trastorno inmunológico caracterizado por la disminución del recuento de plaquetas de forma transitoria o persistente. Puede ser primaria o secundaria en función a la presencia o ausencia de trastornos asociados. Algunos casos se asocian con la infección por Helicobacter pylori, y en estos pacientes el tratamiento erradicador tiene impacto positivo en el recuento de plaquetas. Presentamos cuatro pacientes adultos (dos varones y dos mujeres) con púrpura trombocitopénica inmune secundaria a infección por Helicobacter pylori, los cuales mostraron respuestas favorables al tratamiento erradicador, con mejoría de los recuentos plaquetarios y remisión de las manifestaciones hemorrágicas. Consideramos que debe realizarse la detección rutinaria de esta bacteria en pacientes con púrpura trombocitopénica inmune debido a la elevada prevalencia de la infección en nuestra región y el impacto favorable del tratamiento en el recuento de plaquetas


Immune thrombocytopenic purpura is an immune disorder characterized by a decrease in platelet count transiently or persistently. It can be primary or secondary depending on the presence or absence of associated disorders. Some cases are associated with Helicobacter pyloriinfection, and in these patients eradication treatment has a positive impact on the platelet count. We present four adult patients (two males and two females) with immune thrombocytopenic purpura secondary to Helicobacter pylori infection, which showed favorable responses to eradication treatment, with improvement of platelet counts and remission of hemorrhagic manifestations. We believe that routine detection of this bacterium should be performed in patients with immune thrombocytopenic purpura due to the high prevalence of infection in our region and favorable impact of treatment on the platelet count.


Subject(s)
Helicobacter pylori , Epistaxis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL